Perhaps the Companies resources to implement its agenda are changing.
Has the balance sheet changed due to the use of the Offering and assets appreciating?
Do you think any company stating that they want to improve its Board of Directors is a bad thing’?
I think if there is any chance of the nausea drug succeeding Tauriga must do everything it can to position itself for a future NASDAQ listing.
Look at what just happened to Tauriga’s holding in VTGN. VTGN went from a potential NASDAQ delisting to curing its deficiency for market cap and minimum bid requirement virtually overnight.
In fact, they received a $100 million dollar investment before minimum bid deficiency was cured.
That is how fast circumstances could change in biotech. I have stated for 1 year if Tauriga is to succeed big it will be through a pharma success. Or at least making progress through trial milestones.
Drug trials are difficult. The nausea market is estimated at $7 bil a year. That will be a difficult market to penetrate without a pharma drug partner, at least on the sales and marketing side. But since this is not curing a disease, and only trying to remedy the negative effects from chemotherapy the path to success is slightly easier.
A board with better management would be a good thing going forward.
You should apply?
News 
Market Data 
Discover 
